Last updated: February 16, 2026
What Is the Current Market Status of NDC 70000-0093?
NDC 70000-0093 corresponds to Remogliflozin etabonate, an SGLT2 inhibitor developed for type 2 diabetes management. Its market landscape remains limited but evolving, with key competitors including established drugs such as canagliflozin, dapagliflozin, and empagliflozin.
Remogliflozin was approved in India in 2018 and is in the early stages of commercialization elsewhere. Its global market share remains minimal relative to major SGLT2 inhibitors, primarily due to limited clinical adoption, regulatory status, and distribution channels.
How Does the Pharmacological Profile and Competition Shape the Market?
Pharmacodynamics: Remogliflozin inhibits SGLT2, preventing renal glucose reabsorption, lowering blood sugar levels. It has a similar mechanism to other SGLT2 inhibitors but differs in molecular structure, dosing, and pharmacokinetics.
Competitive Landscape: The global SGLT2 inhibitor market projected to reach USD 24.1 billion by 2026 (Ref. [1]) is dominated by:
- Canagliflozin (Invokana/Invokamet): Approved since 2013; market leader.
- Dapagliflozin (Farxiga): Approved in 2014.
- Empagliflozin (Jardiance): Approved in 2014.
Remogliflozin faces resistance due to existing patents, established safety profiles, and extensive clinical data supporting current therapies.
Regulatory Status: Approved for some markets like India; in other jurisdictions, it remains investigational or under review.
What Are the Price Projections and Market Opportunities?
Current Pricing:
- Remogliflozin’s pricing in India varies but generally remains lower than established drugs, potentially around USD 1–2 per day per patient.
- In comparison, canagliflozin ranges USD 3–4 per day, dapagliflozin USD 3–4, and empagliflozin USD 3–5 (Ref. [2]).
Market Entry Strategy and Price Positioning:
- Entry at a lower price could facilitate uptake in price-sensitive markets like India and Southeast Asia.
- Absence of widespread clinical data restricts widespread adoption in developed markets, limiting price growth potential there.
Future Price Trends:
- As more data accumulates and if regulatory approvals expand, prices could stabilize or increase by 10–20% in targeted markets.
- Launching in the U.S. and EU with proper data could support premium pricing around USD 4–6 per day, aligning with existing SGLT2 inhibitors.
Revenue Projections (2023–2030):
| Year |
Estimated Global Market Share |
Revenue (USD billion) |
Notes |
| 2023 |
1–2% |
0.2–0.4 |
Limited availability, early-stage commercialization. |
| 2025 |
3–5% |
0.6–1.2 |
Expansion into emerging markets, increased clinical data. |
| 2030 |
5–8% |
1.2–2.4 |
Broader adoption if regulatory hurdles clear. |
Risks to Market and Pricing:
- Clinical data may reveal safety concerns, affecting demand.
- Patent challenges or patent expirations for key competitors could influence pricing dynamics.
- Competitive pressure from other emerging SGLT2 inhibitors or new mechanisms.
What Are Key Considerations for Investors and R&D?
- Regulatory horizon: Expect approvals in additional markets within 1–3 years if ongoing trials succeed.
- Manufacturing scale: Cost reductions achievable with increased production volume could enable competitive pricing.
- Partnerships: Licensing and distribution agreements could expand geographic reach.
Key Takeaways
- NDC 70000-0093 (Remogliflozin etabonate) operates in a market dominated by well-established SGLT2 drugs.
- Its current market share and pricing remain constrained by limited clinical data and regulatory approvals outside India.
- Price projections suggest potential for modest growth, especially if global approvals and extensive clinical validation occur.
- Competitive landscape and patent considerations significantly influence market dynamics and pricing.
- Expansion strategies should prioritize clinical data enhancement, regulatory approvals, and targeted market entry.
FAQs
1. What markets are likely to see remogliflozin introduced next?
Emerging markets like Southeast Asia, Africa, and Latin America have potential due to lower pricing sensitivity and ongoing regulatory evaluations.
2. How does remogliflozin compare in efficacy with other SGLT2 inhibitors?
Limited head-to-head clinical data exist; ongoing trials aim to establish comparative efficacy and safety.
3. What are key regulatory hurdles for remogliflozin?
Obtaining approvals outside India requires demonstrating safety, efficacy, and manufacturing quality, particularly in the U.S. and EU.
4. What is the outlook for patent protection?
Patent life varies by jurisdiction; new formulations or combination therapies could extend exclusivity.
5. How might changes in diabetes treatment guidelines impact remogliflozin?
Inclusion in guidelines could accelerate adoption, especially if cost advantages are clear.
Sources
[1] MarketWatch, "SGLT2 Inhibitors Market," 2022.
[2] GoodRx, "SGLT2 Inhibitors Price Comparison," 2022.
